Delphi-based recommendations for the management of cardiovascular comorbidities in patients with psoriatic arthritis and moderate-to-severe psoriasis.

The aim of this study was to generate practical recommendations to assist rheumatologists and dermatologists in the management of cardiovascular (CV) comorbidities in patients with moderate-to-severe psoriasis (MS-PSO) and psoriatic arthritis (PsA). A two-round Delphi study was conducted. A panel of experts rated their agreement with a set of statements (n = 52) on a nine-point Likert scale (1 = totally disagree; 9 = totally agree).

The tissue expression pattern of the AtGRP5 regulatory region is controlled by a combination of positive and negative elements.

The AtGRP5 gene from Arabidopsis thaliana encodes a glycine-rich protein which has a major activity in protoderm-derived cells and is expressed in cells that undergo the first anatomical modifications leading to somatic embryo development. It has been previously demonstrated that its minimum promoter is 316 bp long including the 5'UTR and presents three putative TATA-boxes sequences and several regions that are homologous to previous characterized cis-acting elements. In order to better characterize the AtGRP5 expression and to identify the promoter regions involved in its preferential epidermal expression, in situ hybridization and 5' promoter deletions were employed.